

## Curriculum Vitae

Personal information **Aris Angelis**

### Work experience

---

08/2023

Present

Secretary General for Strategic Planning

Ministry of Health

Hellenic Republic

10/2023

Present

Visiting Associate Professor

Department of Health Services Research and Policy

London School of Hygiene & Tropical Medicine

10/2020

08/2023

Assistant Professor

Department of Health Services Research and Policy

London School of Hygiene & Tropical Medicine

01/2020

02/2020

Visiting Scholar

Center for the Evaluation of Value and Risk in Health

Tufts Medical Center

10/2018

09/2020

Research Fellow

Department of Health Policy, LSE Health

London School of Economics and Political Science

09/2017

09/2020

Guest Teacher/ Lecturer

Department of Health Policy, LSE Health

London School of Economics and Political Science

01/2015

10/2018

Research Officer

LSE Health

London School of Economics and Political Science

09/2010

12/2014

Research Associate

LSE Health

London School of Economics and Political Science

## Education and training

---

09/2012

09/2016

PhD in Health and Pharmaceutical Policy

London School of Economics and Political Science

United Kingdom

09/2008

09/2009

MSc International Health Policy

London School of Economics and Political Science

United Kingdom

09/2007

08/2008

MSc Biopharmacy

King's College London

United Kingdom

10/2004

06/2007

BSc Biochemistry

Imperial College London

United Kingdom

## Additional information

---

### Publications

Briggs A, **Angelis A**, Chen J, Booth D, Davis J, Vaduganathan M, Jhund P. Using composite endpoints in health technology assessment; an illustration of best modelling practice. In press (*Journal of Comparative Effectiveness Research*)

**Angelis A**, Montibeller G, Kanavos P. A structured methodology for essential medicines lists and health emergency stockpiles: experience with the Emergency Medicines Buffer Stock in the United Kingdom. *Social Science & Medicine*, 337(116236). <https://doi.org/10.1016/j.socscimed.2023.116236>

**Angelis A**, Aggarwal A, Miners A, Grieve R, Cairns J, Briggs A (2023). The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep? 116(10):324-330. *Journal of the Royal Society of Medicine*, <https://doi.org/10.1177/01410768231192476>

**Angelis A**, Aggarwal A, Miners A, Grieve R, Cairns J, Briggs A (2023). The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual. *Value in Health*, 26(10):1503-1509. <https://doi.org/10.1016/j.ival.2023.05.015>

**Angelis A**, Polyakov R, Wouters OJ, Torrele E, McKee M (2023). High drug prices are not justified by industry's spending on research and development. *British Medical Journal (BMJ)*, 380:e071710, <http://dx.doi.org/10.1136/bmj-2022-071710>

**Angelis A**, Aggarwal A, Briggs, A (2023). The success of NHS England's Innovative Medicines Fund will depend on its operational details. *Nature Medicine*, 29(2):289-291. <https://doi.org/10.1038/s41591-023-02206-w>

**Angelis A**, Mellerio, JE, & Kanavos, P (2022). Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. *Orphanet Journal of Rare Diseases*, 17(1), 1–346. <https://doi.org/10.1186/s13023-022-02419-1>

**Angelis A**, Suarez Alonso C, Kyriopoulos I, Mossialos E (2022). Funding sources of therapeutic and vaccine clinical trials for COVID-19 vs non-COVID-19 indications, 2020–2021. *JAMA Network Open*, 5(8), e2226892–e2226892. <https://doi.org/10.1001/jamanetworkopen.2022.26892>

Abou-el-Enein A, **Angelis A**, Appelbaum FR, Andrews NC, Bates SE, Bierman A S, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, ... Ioannidis JPA (2021). Evidence generation and reproducibility in cell and gene therapy research: A call to action. *Molecular Therapy. Methods & Clinical Development*, 22, 11–14. <https://doi.org/10.1016/j.omtm.2021.06.012>

**Angelis A**, & Darrow, J. (2021). Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines. *Vaccine*, 39(17), 2328–2330. <https://doi.org/10.1016/j.vaccine.2021.03.053>

**Angelis A**, Baltussen R, Tervonen T. How should we price Covid-19 vaccines? The need of societal perspective in value measurement for pandemics. *American Journal of Public Health*. 2021; 11(2): 205-208. <https://doi.org/10.2105/AJPH.2020.306066>

**Angelis A**, Phillips LD. Advancing structured decision-making in drug regulation at the FDA and EMA. *British Journal of Clinical Pharmacology*. 2021; 87(2): 395-405. <https://doi.org/10.1111/bcp.14425>

**Angelis A**, Naci H, Hackshaw A. Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies. *PharmacoEconomics*. 2020; 38(12): 1297-1308. <https://doi.org/10.1007/s40273-020-00956-w>

**Angelis A**, Kanavos P, Phillips LD. ICER Value Framework 2020 update: recommendations on the aggregation of benefits and contextual considerations. *Value in Health*. 2020;23(8). <https://doi.org/10.1016/j.ival.2020.04.1828>

**Angelis A**, Thursz M, Ratzu V, et al. Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. *Medical Decision Making*. 2020;40(6):830-845. <https://doi.org/10.1177/0272989X20940672>

**Angelis A**, Linch M, Montibeller G, Molina Lopez T, Zawada A, Orzel K, Arickx F, Espin J, Kanavos P (2020). Multiple Criteria Decision Analysis in the context of HTA across four EU Member States: piloting the Advance Value Framework. *Social Science & Medicine*, 246 (112595). <https://doi.org/10.1016/j.socscimed.2019.112595>

Tervonen T, **Angelis A**, Hockley K, Pignatti F, Phillips LD (2019). Quantifying Preferences in Drug Benefit - Risk Decisions. *Clinical Pharmacology & Therapeutics*, 106 (5), 955-959. <https://doi.org/10.1002/cpt.1447>

Kanavos P, **Angelis A**, Drummond M (2019). An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed? *The European Journal of Health Economics*, 20 (3), 329-332. <https://doi.org/10.1007/s10198-019-01037-2>

**Angelis A**, Kanavos P (2019). Comment on: "Does MCDA Trump CEA?". *Applied Health Economics and Health Policy*, 17 (1), 123-124. <https://doi.org/10.1007/s40258-018-0445-z>

**Angelis A** (2018). Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden. *MDM Policy & Practice*, 3 (2), 1-17. <https://doi.org/10.1177/2381468318796218>

**Angelis A**, Lange A, Kanavos P (2018). Using health technology assessment to assess the value of new medicines: Results of a systematic review and expert consultation across eight European countries. *The European Journal of Health Economics*, 19 (1), 123-152. <https://doi.org/10.1007/s10198-017-0871-0>

**Angelis A**, Montibeller G, Hochhauser D, Kanavos P (2017). Applying Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer with multiple stakeholders, *BMC Medical Informatics and Decision Making*, 17 (149), 1-25 <https://doi.org/10.1186/s12911-017-0524-3>

**Angelis A**, Kanavos P. Multiple criteria decision analysis (MCDA) for evaluating new medicines: the Advance Value Framework (2017). *Social Science & Medicine*, 188, 137-156. <https://doi.org/10.1016/j.socscimed.2017.06.024>

Jackson TL, Nicod EM, **Angelis A**, Grimaccia F, Prevost AT, Simpson ARH, Kanavos P (2017). Pars Plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature, a synthesis of the literature. *Retina*, 37 (5), 886-895. doi: 10.1097/IAE.0000000000001280

**Angelis A**, Kanavos P, Montibeller G (2017). *Resource allocation and priority setting in health care: a multi-criteria*

decision analysis problem of value? *Global Policy*, 8 (S2), 76-83. <https://doi.org/10.1111/1758-5899.12387>

**Angelis A**, Tordrup D, Kanavos P (2017). Is the funding of public national health systems sustainable over the long term? Evidence from eight OECD countries. *Global Policy*, 8 (S2), 7-22. <https://doi.org/10.1111/1758-5899.12341>

**Angelis A**, Kanavos P (2016). A Critique to ASCO's Value Assessment Framework for Cancer Treatments: Putting Methodological Robustness First. *Journal of Clinical Oncology*, 34 (24), 2935-2936, <http://doi.org/10.1200/JCO.2015.64.9673>

**Angelis A**, Kanavos P, Lopez-Bastida J, Linertova R, Serrano-Aguilar P (2016). Social and Economic Costs and Health-Related Quality of Life in Non-institutionalised Patients with Juvenile Idiopathic Arthritis in the United Kingdom. *BMC Musculoskeletal Disorders*, 17 (1). 321. <https://doi.org/10.1186/s12891-016-1129-1>

**Angelis A**, et al (2016). Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. *The European Journal of Health Economics*, 17 (1), 31-42 <https://doi.org/10.1007/s10198-016-0783-4>

**Angelis A**, Kanavos P (2016). [Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment](https://doi.org/10.1007/s40273-015-0370-z). *PharmacoEconomics*, 34 (5), 435-446 <https://doi.org/10.1007/s40273-015-0370-z>

Nicod E, Jackson TL, Grimaccia F, **Angelis A**, Costen M, Haynes R, Hughes E, Pringle E, Zambarakji H, Kanavos P (2015). [Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach](https://doi.org/10.1007/s10198-015-0741-6). *The European Journal of Health Economics*, 17 (8). 991-999. <https://doi.org/10.1007/s10198-015-0741-6>

**Angelis A**, Kanavos P, López-Bastida J, Linertová R, Nicod E, Serrano-Aguilar P (2016). [Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom](https://doi.org/10.1186/s12913-015-1061-3). *BMC Health Services Research*, 15 (428). <https://doi.org/10.1186/s12913-015-1061-3>

Tervonen T, Naci H, van Valkenhoef G, Ades AE, **Angelis A**, Hillege HL, Postmus D (2015). [Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention](https://doi.org/10.1177/0272989X15587005). *Medical Decision Making*, 35 (7). 859-871. <https://doi.org/10.1177/0272989X15587005>

**Angelis A**, Tordrup D, Kanavos P (2015). [Socio-economic burden of rare diseases: a systematic review of cost of illness evidence](https://doi.org/10.1016/j.healthpol.2014.12.016). *Health Policy*, 119 (7). 964-979. <https://doi.org/10.1016/j.healthpol.2014.12.016>

Kanavos P, **Angelis A** (2014). [Acquiring pharmaceutical industry assets in the UK: 1 + 1 = 1?](https://doi.org/10.1007/s40290-014-0066-2) *Pharmaceutical Medicine*, 28 (5) 245-248. <https://doi.org/10.1007/s40290-014-0066-2>

Jackson TL, Nicod EM, **Angelis A**, Grimaccia F, Prevost AT, Simpson ARH, Kanavos P (2013). [Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy](https://doi.org/10.1097/IAE.0b013e3182a6b3e2). *Retina*, 33 (10). 2012-2017. doi: 10.1097/IAE.0b013e3182a6b3e2

Jackson TL, Nicod E, Simpson A, **Angelis A**, Grimaccia F, Kanavos P (2013). [Symptomatic vitreomacular adhesion](https://doi.org/10.1097/IAE.0b013e31829232fd). *Retina*, 33 (8). 1503-1511. doi: 10.1097/IAE.0b013e31829232fd.

Jackson TL, Nicod E, **Angelis A**, Grimaccia F, Prevost AT, Simpson A, Kanavos P (2013). [Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion](https://doi.org/10.1097/IAE.0b013e31828991d6). *Retina*, 33 (6). 1099-1108. doi: 10.1097/IAE.0b013e31828991d6.

Tordrup D, **Angelis Aris**, Kanavos P (2013). [Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey](https://doi.org/10.1007/s40258-013-0056-7). *Applied Health Economics and Health Policy*, 11 (6). 639-652. <https://doi.org/10.1007/s40258-013-0056-7>

## Projects

2024 - Present

European Commission Technical Support Instrument (Coordinating Authority)

Strengthening the national framework for the implementation of the EU HTA Regulation 2021/2282: capacity building and harmonization

2022 – 2023

AstraZeneca (Co-leader)

Treatment effects from clinical trials using composite endpoints: the case of SGLT2 inhibitors

2021 – 2022

National Institute for Health and Care Excellence (NICE)

Advancing value assessment methods for cancer drugs focusing on the Cancer Drugs Fund (NICE Scholarship)

2020 – 2023

European Society for Medical Oncology (Co-leader)

Design and development of a universal evaluation model for cancer drugs

2018 – 2021

European Commission Horizon 2020 (Leading researcher)

Improved methods and actionable tools for enhancing HTA (IMPACT-HTA)

2018 – 2020

Department of Health and Social Care (Co-leader)

A structured methodology for the Emergency Medicines Buffer Stock in the UK

2017 – 2018

Novartis Pharmaceuticals (Co-leader)

Multiple criteria decision analysis for the early assessment non-alcoholic steatohepatitis (NASH) compounds in drug development

2017 – 2018

European Bank for Reconstruction and Development (Co-leader)

Mapping the regulatory environments in the pharmaceutical sector in the Middle East and North Africa region

2013 – 2015

European Commission Framework Programme 7 (Leading researcher)

Advancing and strengthening the methodological tools and practices relating to the application and implementation of HTA (ADVANCE-HTA)

2010 – 2012

European Commission 2nd Programme of Community Action in the Field of Public Health (Researcher)

Social economic burden and health-related quality of life of patients with rare diseases in Europe (BURQOL-RD)

## Memberships

### Ministry of Health, Hellenic Republic

- Chairman of Medicines Shortages Monitoring Committee
- Chairman of Pharmaceutical Expenditure Monitoring Committee
- Chairman of the Working Group for the National Response Mechanism to the HERA Joint Procurement Processes
- Coordinator of the Working Group for the Reorganisation of the National Organization for Health Care Services into a Modern Insurance Institution
- Coordinator of the Working Group for the Upgrading and Modernisation of the National Medicines Organisation
- Member of Interministerial Monitoring Committee of the Ministry of Health's Finances
- Member of Central Board of Health Districts

### Health Emergency Preparedness and Response Authority, European Commission

- Member of the Steering Group of the Critical Medicines Alliance
- Co-chair of Working Group 2 of the Critical Medicines Alliance
- Member of Working Group 1 of the Critical Medicines Alliance
- Member of Steering Committee of the Joint Procurement Agreement
- Member of Specific Procurement Procedure Steering Committee - Covid-19 mRNA Vaccines
- Member of Specific Procurement Procedure Steering Committee - Protein Based Covid-19 Vaccines 2024
- Member of Specific Procurement Procedure Steering Committee - Veklury 2024
- Member of Specific Procurement Procedure Steering Committee - Zoonotic Influenza Vaccine
- Member of Advisory Forum

### Organisation for Economic Co-operation and Development

- Health Committee, OECD Health Data National Correspondents and Health Account Experts
- Member of Expert Group on Pharmaceutical and Medical Devices

## Other Relevant Information

### HONORS, PRIZES AND SCHOLARSHIPS

2021 National Institute for Health and Care Excellence Scholar

- 2015 Young Forum Gastein Scholar, World Health Organisation/European Commission
- 2013 Post Graduate Travel Fund award (x3 years), London School of Economics
- 2009 Graduated with honours, MSc London School of Economics
- 2008 Gorrod Prize, top student in specialised modules, MSc King's College London
- 2008 Graduated with distinction, MSc King's College London
- 2007 Graduated with honours, BSc Imperial College London